Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Session 2 – EGFR E20I mutations inhibitor drug development

Phase II Clinical development of EGFR E20I inhibitors and emerging evidence from RWD and ongoing trials


05 Dec 2022


Session 2 – EGFR E20I mutations inhibitor drug development


Targeted Therapy;  Clinical Research

Tumour Site

Non-Small Cell Lung Cancer


S. M. Lim, KR


Login to access the resources on OncologyPRO.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.